DeutschNewstral
Article
Iinvezz.com on 2023-12-01 14:50
AbbVie bolsters portfolio with $10.1 billion ImmunoGen buyout for cancer therapy
Related news
Drugmaker AbbVie to spend over $10 billion on ImmunoGen to juice its cancer-fighting treatment portfoliopressherald.com
Patrick Industries Bolsters Portfolioinsideindianabusiness.com
ImmunoGen, Inc. v. Hirshfeld (Fed. Cir. 2022)jdsupra.com
Standard Solar bolsters Md. ownership portfoliothedailyrecord.com
CBZ bolsters property portfolio to protect valuenewsday.co.zw
GoDaddy bolsters domain name portfolio with acquisitionbizjournals.com
Stillman Property Management bolsters Fairfield portfoliowestfaironline.com- SunEdison’s TerraForm completes wind farm portfolio buyoutbizjournals.com
- Alvotech Files Suit Against AbbVie to Invalidate Humira Patent Portfoliojdsupra.com
- Raleigh pharma bolsters portfolio security with patent approvalbizjournals.com
- Takeda deal affords ImmunoGen both cash and credibility boostbizjournals.com
- ImmunoGen hires former Shire, Genzyme exec as new CEObizjournals.com
- ImmunoGen axes 75% of staff to fund new clinical trialbizjournals.com
- MImmunoGen, Solid Biosciences and Insys lead Wednesday’s biotech losersmarketwatch.com
- Florida firm bolsters Resource Square portfolio with $24.8M acquisitionbizjournals.com
Roche Bolsters Cancer Portfolio With $1.7 Billion Ignyta Dealwsj.com- Louisville-based Payment Alliance bolsters its portfolio with ATM acquisitionbizjournals.com
Philippines’ Filinvest Development Bolsters Its Portfolio, Undeterred By Business DownturnsForbes- Florida firm bolsters local portfolio with $98.6M apartment acquisitionbizjournals.com
- What’s Happening With AbbVie Stock?Forbes